The Application dimension of the Diabetes Mellitus Treatment market is divided into four primary segments: Insulin therapy, Oral hypoglycemics, Injectable non‑insulin agents, and Combination therapy. Insulin therapy remains the largest contributor, accounting for roughly 45% of market revenue, driven by its indispensable role in managing Type 1 diabetes and advanced Type 2 cases. Oral hypoglycemics represent about 35% of the market, reflecting the broad adoption of metformin, sulfonylureas, and newer SGLT‑2 inhibitors for early‑stage Type 2 patients. Injectable non‑insulin agents, such as GLP‑1 receptor agonists, capture an estimated 15% share, fueled by their dual glucose‑lowering and cardiovascular benefits. Finally, Combination therapy—integrating insulin with oral or injectable agents—contributes the remaining 5%, primarily in patients requiring intensified glycemic control. Together, these application categories shape the overall market size and inform the strategic focus of manufacturers within the Diabetes Mellitus Treatment segmentation.